By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Promedior 

5 Great Valley Parkway
Suite 300
Malvern  Pennsylvania  19355  U.S.A.
Phone: 610-560-1435 Fax: 610-560-1436


SEARCH JOBS








Company News
Promedior Announces Completion Of Patient Enrollment Milestones In Phase 2 Clinical Studies Of PRM-151 In Both Idiopathic Pulmonary Fibrosis And Myelofibrosis 12/2/2016 9:52:38 AM
Promedior Presents Positive Phase II Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting 12/10/2015 8:31:50 AM
Promedior Announces Initiation Of A Phase II Clinical Study Of PRM-151 In Idiopathic Pulmonary Fibrosis (IPF) 9/8/2015 11:32:09 AM
Bristol-Myers Squibb (BMY) Bags Rights to Buy Promedior in Deal Worth $1.25 Billion 8/31/2015 6:41:58 AM
Promedior Presents Additional Positive Phase 2 Data For PRM-151 In Myelofibrosis At EHA Annual Meeting 6/12/2015 9:32:36 AM
Promedior Announces Presentation Of Additional Positive Phase II Data On PRM-151 In Myelofibrosis At The Upcoming Congress Of The European Hematology Association 6/4/2015 8:48:57 AM
Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting 12/9/2014 9:46:55 AM
Promedior Receives Fast Track Designation For PRM-151 For The Treatment Of Myelofibrosis 11/3/2014 10:46:50 AM
Promedior Announces Presentation Of Retrospective Quantitative Imaging Analysis Of Phase 1b Data In Idiopathic Pulmonary Fibrosis 9/22/2014 9:16:57 AM
Promedior Receives U.S. Orphan Drug Designation For PRM-151 For The Treatment Of Myelofibrosis 9/2/2014 11:28:09 AM
12345
//-->